ClinicalTrials.gg
WithdrawnNCT00796601Updated Nov 29, 2018

Maintenance of Efficacy.

A Phase 3 interventional study of Esreboxetine and Placebo in Fibromyalgia, sponsored by Pfizer. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-29.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Fibromyalgia by Pfizer — none open to participants now, none under way, none of them phase 3. Fibromyalgia · Pfizer.

Enrollment
12th of 12
0 · median 283
Started
2009
with 1 other
Phase 3
5 of 12
none open now
Registered
10th of 12
by date

Among the 12 studies in Fibromyalgia by Pfizer, this one is the 12th largest by enrollment, is one of 2 that started in 2009, is one of 5 in phase 3, and was the 10th registered.

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

None of the 12 studies in Fibromyalgia by Pfizer is open now. The open studies under Fibromyalgia, anywhere →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Fibromyalgia by Pfizer as a file.
02

Study summary

The hypothesis of Study A6061054 is to demonstrate superiority of efficacy of esreboxetine at 3 and 6 months compared to placebo.

03

Conditions studied

  • Fibromyalgia

Browse trials for

Keywords

  • double-blind placebo-controlled maintenance of efficacy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must meet the American College of Rheumatology (ACR) criteria for fibromyalgia
  • Pain score greater than or equal to 4 on an 11-point NRS
  • FIQ-Total score greater than or equal to 45 points

Exclusion criteria

Exclusion Criteria:

  • Other severe pain that may confound assessment or self evaluation of the pain associated with fibromyalgia
  • Any rheumatic disorder, non-focal rheumatic disease (other than fibromyalgia), active infection, or untreated endocrine disorder
  • Uncontrolled hypertension Pending Worker's Compensation; Current or recent diagnosis or episode of major depressive disorder, dysthymia and/or uncontrolled depression; Subjects to be at risk of suicide;
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Esreboxetine

    Drug: Esreboxetine

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Film coated tablets (2, 6, 8, 10 mg esreboxetine), once daily for 6 months

  • DrugPlacebo

    Film coated tablets (0 mg esreboxetine), once daily for 6 months

06

What researchers measure

Primary outcomes

  1. Change from baseline to 3 and 6 months in the mean daily pain rating score measured by the 11 point pain intensity Numerical Rating Scale (NRS).

    Time frame: 6 months

  2. Change from baseline to 3 and 6 months in the FIQ-Total score

    Time frame: 6 months

Secondary outcomes

  1. Pain (including other measures of daily pain and responder analyses);

    Time frame: 6 months

  2. Function (including sub-scales of the FIQ, responder analyses of FIQ and SF-36);

    Time frame: 6 months

  3. Global efficacy measures PGIC);

    Time frame: 6 months

  4. Sleep (MOS);

    Time frame: 6 months

  5. Work productivity;

    Time frame: 6 months

  6. Depression (HADS)

    Time frame: 6 months

  7. Safety (vital signs, ECG, laboratory, suicidal ideation)

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2009 (actual). Primary completion is estimated for May 2010, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2008
First posted
Nov 24, 2008
StartActual
May 1, 2009
Primary completionEst.
May 1, 2010
CompletionEst.
Nov 1, 2010
Last update
Nov 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00796601
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 24, 2008
Start date
May 1, 2009
Primary completion
May 1, 2010 (estimated)
Completion
Nov 1, 2010 (estimated)
Last update
Nov 29, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esreboxetine

Start the discussion